TTY Biopharm Co Ltd (4105) — Cash Flow Reinvestment Rate
TTY Biopharm Co Ltd (4105) has a Cash Flow Reinvestment Rate of 0.26x as of December 2025, reinvesting NT$202.24 Million (capex NT$34.72 Million plus investments NT$-167.51 Million) from operating cash flow of NT$778.89 Million. Check 4105 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
TTY Biopharm Co Ltd Cash Flow Reinvestment Rate (2017–2025)
Historical reinvestment intensity for TTY Biopharm Co Ltd across 9 annual periods. Explore 4105 debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Annual Cash Flow Reinvestment Rate for TTY Biopharm Co Ltd (2017–2025)
Year-by-year capital reinvestment analysis for TTY Biopharm Co Ltd. For live market cap and broader valuation context, see market value of TTY Biopharm Co Ltd.
| Year | Reinvestment Rate | Total Reinvested (TWD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.18x | NT$323.19 Million | NT$1.76 Billion | NT$150.83 Million | ▼ -5.7% |
| 2024 | 0.19x | NT$262.47 Million | NT$1.35 Billion | NT$134.29 Million | ▲ +106.5% |
| 2023 | 0.09x | NT$102.21 Million | NT$1.09 Billion | NT$99.58 Million | ▼ -31.6% |
| 2022 | 0.14x | NT$170.18 Million | NT$1.24 Billion | NT$135.50 Million | ▲ +96.1% |
| 2021 | 0.07x | NT$88.25 Million | NT$1.26 Billion | NT$74.15 Million | ▼ -92.5% |
| 2020 | 0.93x | NT$490.68 Million | NT$526.35 Million | NT$181.86 Million | ▲ +306.0% |
| 2019 | 0.23x | NT$277.82 Million | NT$1.21 Billion | NT$69.86 Million | ▼ -86.7% |
| 2018 | 1.73x | NT$1.86 Billion | NT$1.07 Billion | NT$74.09 Million | ▲ +155.8% |
| 2017 | 0.68x | NT$675.00 Million | NT$996.52 Million | NT$96.79 Million | — |